ASX:ALT

Stock Analysis Report

Executive Summary

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Analytica has significant price volatility in the past 3 months.
  • Analytica is not covered by any analysts.

Share Price & News

How has Analytica's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-25.0%

ASX:ALT

4.5%

AU Medical Equipment

-0.4%

AU Market


1 Year Return

-50.0%

ASX:ALT

9.9%

AU Medical Equipment

2.1%

AU Market

ALT underperformed the Medical Equipment industry which returned 9.9% over the past year.

ALT underperformed the Market in Australia which returned 2.1% over the past year.


Share holder returns

ALTIndustryMarket
7 Day-25.0%4.5%-0.4%
30 Day-25.0%-0.5%-2.5%
90 Day-40.0%9.8%0.5%
1 Year-50.0%-50.0%12.0%9.9%8.0%2.1%
3 Year-57.1%-57.1%41.9%35.5%32.4%14.9%
5 Year-90.7%-91.4%135.9%115.1%39.6%8.3%

Price Volatility Vs. Market

How volatile is Analytica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Analytica undervalued based on future cash flows and its price relative to the stock market?

7.32x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Analytica to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Analytica to establish if it is available at substantial discount.


Price Based on Earnings

Analytica is loss making, we can't compare its value to the AU Medical Equipment industry average.

Analytica is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Analytica, we can't assess if its growth is good value.


Price Based on Value of Assets

Analytica is overvalued based on assets compared to the AU Medical Equipment industry average.


Next Steps

Future Growth

How is Analytica expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Analytica performed over the past 5 years?

4.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Analytica does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Analytica's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Analytica's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Analytica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Analytica has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Analytica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Analytica's financial position?


Financial Position Analysis

Analytica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Analytica's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Analytica has no debt.

Analytica had no debt 5 years ago.


Balance Sheet

Low level of unsold assets.

Analytica has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Analytica has less than a year of cash runway based on current free cash flow.

Analytica has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.2% each year.


Next Steps

Dividend

What is Analytica's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Analytica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Analytica's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Analytica has not reported any payouts.

Unable to verify if Analytica's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Analytica has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Analytica's salary, the management and board of directors tenure and is there insider trading?

7.4yrs

Average board tenure


CEO

Geoff Daly 0

5.5yrs

Tenure

AU$240,900

Compensation

Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Opera ...


CEO Compensation Analysis

Geoff's remuneration is lower than average for companies of similar size in Australia.

Geoff's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

7.4yrs

Average Tenure

The tenure for the Analytica board of directors is about average.


Insider Trading

More shares have been bought than sold by Analytica individual insiders in the past 3 months.


Recent Insider Transactions

BuyAU$514,06507 Jun 19
Michael Monsour
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares102,632,612
Max PriceAU$0.005
BuyAU$77,05207 Jun 19
Ross Mangelsdorf
EntityIndividual
Role
Member of the Board of Directors
CFO & Executive Director
Shares15,414,040
Max PriceAU$0.005

Ownership Breakdown


Management Team

  • Bryan Dulhunty

    Company Secretary

    • Tenure: 6.8yrs
    • Compensation: AU$19.08k
  • Michael Monsour

    Executive Chairman

    • Tenure: 15.2yrs
    • Compensation: AU$82.13k
  • Geoff Daly

    Chief Executive Officer

    • Tenure: 5.5yrs
    • Compensation: AU$240.90k
  • Ross Mangelsdorf

    CFO & Executive Director

    • Tenure: 10.8yrs
    • Compensation: AU$210.73k
  • Chelsea Cornelius

    Product Development & Operations Manager

    • Tenure: 0.0yrs
  • Megan Henken

    Vice President of Global Marketing

    • Tenure: 0.0yrs

Board Members

  • Peter Corr (71yo)

    Non-Executive Director

    • Tenure: 2.3yrs
    • Compensation: AU$72.76k
  • Michael Monsour

    Executive Chairman

    • Tenure: 15.2yrs
    • Compensation: AU$82.13k
  • Ross Mangelsdorf

    CFO & Executive Director

    • Tenure: 10.8yrs
    • Compensation: AU$210.73k
  • Thomas Lönngren

    Non-Executive Director

    • Tenure: 4.0yrs
    • Compensation: AU$56.82k

Company Information

Analytica Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Analytica Limited
  • Ticker: ALT
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$14.078m
  • Shares outstanding: 3.52b
  • Website: https://www.analyticamedical.com

Location

  • Analytica Limited
  • 320 Adelaide Street
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2000
ALTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2000

Biography

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company’s lead product is PeriCoach system, an e-health treatment system for w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 10:32
End of Day Share Price2019/08/21 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.